Keckley Report November 23, 2020
Paul Keckley

Last week, Moderna joined Pfizer in announcing promising results of their messenger RNA vaccines and their intent to file for emergency use authorization with the FDA within days. A third vaccine by Astra Zeneca-Oxford University, significant because it is a viral vector vaccine, is not far behind. And Saturday, a second drug by Regeneron received FDA emergency use approval on the heels of Eli Lilly’s approval earlier this month. That’s encouraging.

Arguably, Operation Warp Speed is a resounding success: the investment of $10.75 billion in vaccine development (Pfizer- BioNTech $1.95 billion, Moderna $2.5 billion, J&J $1.5 billion, Astra Zeneca $1.2 billion, Sanofi with GSK $2 billion, and Novavax $1.6 billion) brings hope for a return to normalcy next year. But...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Healthcare System, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Public Health / COVID
The Ripple Effect: Ways to Make Health in All Policies Stick in Kansas and Beyond to Enhance Health and Equity
Research Funding Is Needed To Support An Effective, Equitable, And Sustainable Public Health System
Covid’s scientific silver lining: A chance to watch the human immune system respond in real time
New Data: Long COVID Cases Surge
New federal health IT strategy increases focus on public health, AI

Share This Article